levocetirizine dihydrochloride tablet, film coated
bryant ranch prepack - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. the use of levocetirizine dihydrochloride is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2) ]. patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis. children 6 months to 11 years of age with impaired renal function. risk summary available data from published literature and postmarketing experience with levocetirizine use in pregnant women are insufficient to identify any drug-associated risks of miscarriage, birth defects, or adverse maternal or fetal outcomes. in animal reproduction studies, there was no evidence of fetal harm with administration of levocetirizine by the oral r
levocetirizine dihydrochloride tablet
bryant ranch prepack - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with perennial allergic rhinitis in children 6 months to 2 years of age. levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. the use of levocetirizine dihydrochloride tablets is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2) ]. patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis. children 6 months to 11 years of age with impaired renal function. risk summary available data from published literature and postmarketing experience with levocetirizine use in pregnant women are insufficient to identify any drug-associated risks of miscarriage, birth
levocetirizine dihydrochloride 5 mg film-coated tablets
cipla (eu) limited hillbrow house, hillbrow road, esher, surrey, kt10 9nw, united kingdom - levocetirizine dihydrochloride - film-coated tablet - levocetirizine dihydrochloride 5 mg - antihistamines for systemic use
levocetirizine dihydrochloride fair-med 5mg film-coated tablets
fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - levocetirizine dihydrochloride - film-coated tablet - levocetirizine dihydrochloride 5 mg - antihistamines for systemic use
levocetirizine teva 5mg film-coated tablets
teva pharma b.v. swensweg 5, 2031 ga haarlem, netherlands - levocetirizine dihydrochloride - film-coated tablet - levocetirizine dihydrochloride 5 mg - antihistamines for systemic use
levocetirizine 5mg tablets
teva uk ltd - levocetirizine dihydrochloride - oral tablet - 5mg
levocetirizine 5mg tablets
a a h pharmaceuticals ltd - levocetirizine dihydrochloride - oral tablet - 5mg
levocetirizine 5mg tablets
alliance healthcare (distribution) ltd - levocetirizine dihydrochloride - oral tablet - 5mg
levocetirizine 5mg tablets
consilient health ltd - levocetirizine dihydrochloride - oral tablet - 5mg
levocetirizine 5mg tablets
phoenix healthcare distribution ltd - levocetirizine dihydrochloride - oral tablet - 5mg